Madopark Quick Mite

Levodopa/Benserazide, the active ingredient in Madopark Quick Mite, is a dopamine precursor/DOPA decarboxylase inhibitor combination presented as an oral tablet for oral use. It is used to treat Parkinson's disease in adults by restoring central dopamine levels, helping to improve motor function and reduce rigidity.

GNH USA supplies Madopark Quick Mite as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing reliable sourcing for hospitals, pharmacies and clinics worldwide. All batches are manufactured under strict quality control and are distributed under secure logistics to ensure product integrity.

Madopark Quick Mite, a levodopa/benserazide combination, is indicated for the management of Parkinsonian disorders.

- Parkinson's disease (early stage): improves motor symptoms such as tremor and bradykinesia. - Parkinson's disease (advanced stage): helps maintain functional mobility when used with adjunct therapies. - Parkinsonian syndrome secondary to dopamine deficiency: restores dopaminergic activity to reduce rigidity and improve gait.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Dyskinesia: involuntary movements, especially with higher doses. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Severe hypotension: marked drop in blood pressure leading to fainting. - Cardiac arrhythmias: irregular heart rhythms. - Psychosis: hallucinations or delusional thoughts. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, consider patient‑specific factors and monitor for adverse reactions. - Renal impairment: adjust dose and monitor renal function. - Hepatic disease: use with caution; monitor liver enzymes. - Cardiovascular disease: watch for hypotension and arrhythmias. - Concomitant MAO‑B inhibitors: avoid due to risk of hypertensive crisis. - Pregnancy and lactation: safety not established; only use if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Drug interactions may alter efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may diminish antiparkinson effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Iron supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - Antihypertensives: additive blood‑pressure lowering effect. - SSRIs and SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.